XGN Exagen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XGN

Price (delayed)

$4.79

Market cap

$115.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.89

Enterprise value

$121.36M

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 27
Relative Valuation: Rel. Valuation: 24
Relative Profitability: Rel. Profitability: 20

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and ...

Highlights
Exagen's revenue has increased by 21% YoY and by 2.7% from the previous quarter
The company's gross profit rose by 19% YoY and by 2.8% QoQ
Exagen's equity has soared by 125% YoY but it has decreased by 17% from the previous quarter
XGN's quick ratio has surged by 61% year-on-year but it is down by 2.3% since the previous quarter
The company's net income fell by 30% YoY
XGN's debt is up by 16% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.exagen.com
Peers: OPCH PNTG

Key stats

What are the main financial stats of XGN

XGN stock price

How has the Exagen stock price performed over time
Intraday
5.51%
1 week
-5.71%
1 month
54.52%
1 year
-35.01%
YTD
-21.22%
QTD
59.67%

Financial performance

How have Exagen's revenue and profit performed over time
Revenue
$68.38M
Gross profit
$39.88M
Operating income
-$14.12M
Net income
-$20.17M
Gross margin
58.3%
Net margin
-29.5%
The company's net income fell by 30% YoY
Exagen's revenue has increased by 21% YoY and by 2.7% from the previous quarter
The company's gross profit rose by 19% YoY and by 2.8% QoQ
The operating margin has grown by 17% YoY and by 2.4% from the previous quarter

Price vs fundamentals

How does XGN's price correlate with its fundamentals

Growth

What is Exagen's growth rate over time

Valuation

What is Exagen stock price valuation
P/E
N/A
P/B
7.98
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.77
The EPS has contracted by 6% YoY but it has grown by 4.3% from the previous quarter
Exagen's equity has soared by 125% YoY but it has decreased by 17% from the previous quarter
XGN's price to book (P/B) is 105% higher than its 5-year quarterly average of 3.7 but 7% lower than its last 4 quarters average of 8.1
The P/S is 34% less than the last 4 quarters average of 2.4 and 17% less than the 5-year quarterly average of 1.9
Exagen's revenue has increased by 21% YoY and by 2.7% from the previous quarter

Efficiency

How efficient is Exagen business performance
The company's return on equity rose by 15% YoY and by 10% QoQ
The company's return on invested capital rose by 7% QoQ and by 2.8% YoY
The ROS has grown by 6% from the previous quarter and by 6% YoY
Exagen's return on assets has increased by 4.1% QoQ

Dividends

What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XGN.

Financial health

How did Exagen financials performed over time
The total assets is 38% greater than the total liabilities
XGN's quick ratio has surged by 61% year-on-year but it is down by 2.3% since the previous quarter
Exagen's current ratio has increased by 50% YoY
XGN's debt is 88% greater than its equity
Exagen's equity has soared by 125% YoY but it has decreased by 17% from the previous quarter
The debt to equity has contracted by 49% YoY but it has grown by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.